30 closest matches · ranked by relevance
Chalazion Unspecified Eye, Unspecified Eyelid · Chalazion Left Eye, Unspecified Eyelid · Chalazion Right Eye, Unspecified Eyelid
Primary: Number of Participants With Complete Resolution — 13; 12; 11 participants
Chalazion
Primary: The Proportions of Participants Who Experienced Complete Response of the Study Chalazion by Day 15 ± 1 — 28; 32 Participants — p=0.579
Chalazion
Primary: Time Taken for a Complete Resolution of the Chalaziosis — 51.2; 28.4 days
Chalazion · Dry Eye Syndromes
Primary: Meibomian Gland Assessment (Total Meibomian Gland Secretion Score) — 6.3; 5.6; 14.3; 6.1 Scores on a scale
Chalazion · Hordeolum
Primary: Treatment Emergent Adverse Events — 2; 0; 1; 1 participants
Chalazion · Dry Eye Syndromes
Primary: Association Between Screening Methods (Meibomian Gland Expression) and Treatment Effectiveness Outcomes (Total Meibomian Gland Score) — 0.4816 Correlation coefficient…
Dry Eye
Primary: Non-invasive Tear Break up Time (TBUT) — 3.9; 4.0 seconds
Dry Eye Syndromes · Dry Eye · Meibomian Gland Dysfunction
Primary: Score and Change From Baseline in Tear Break Up Times (TBUT), as Assessed by a Masked Rater — 4.0; 1.9; 3.4; 4.7 seconds
Blepharitis · Dry Eye Syndrome
Primary: Mean Change in Total Meibomian Gland Score — 12.8; 1.9 Change in Meibomian Gland Score
Meibomian Gland Dysfunction · Dry Eye
Primary: Dry Eye Questionnaire 5 (DEQ-5) Score — 11.8; 11.8 score on a scale — p=0.02
Meibomian Gland Dysfunction · Dry Eye Syndromes · Dry Eye
Primary: Changes in Tear Break Up Times (TBUT) to the 4-weeks Follow-up Exam — 4.3; 4.6; 3.0; 2.7 seconds
Posterior Blepharitis
Primary: Change of Blepharitis Symptoms Score — 1.8; 2.8 score — p=0.03
Blepharitis
Primary: Global Response to Therapy — 16; 41 eyes — p=.001
Meibomian Gland Dysfunction · Posterior Blepharitis
Primary: Ocular Surface Disease Index — 56.6; 46.4; 48.4 units on a scale
Meibomian Gland Dysfunction
Primary: Tear Film Breakup Time — 4.65; 4.42 seconds — p=0.550
Meibomian Gland Dysfunction
Primary: Meibum Gland Secretion Score (MGS) — 0.5; 7.4 score on a scale
Trachoma
Primary: Number of Eyelids With Presence of Recurrent Trichiasis — 948; 1062; 721; 612 eyelids
Evaporative Dry Eye
Primary: Change From Baseline in Meibomian Gland Secretion (MGS) Total Score — 12.3; 14.5 score on a scale — p=<0.0001
Chronic Blepharitis
Primary: Change in the Number of Demodex Mites — -3; -0.4 Mites
Blepharitis
Primary: Change From Baseline in Ocular Discomfort — -4.1; -2.4 score on a scale
Meibomian Gland Dysfunction · Dry Eye
Primary: Mean Change in Meibomian Gland Score From Baseline at 3 Months — 12.4; 1.4 units on a scale — p=<0.0001
Dry Eye Disease · Meibomian Gland Dysfunction · Cataract Senile
Primary: Change in Lipid Layer Thickness (LLT) From 2 Weeks Pre-operative Baseline to 4 Weeks Post-operative Follow-up — -1.9; 19.5 Nanometers
Posterior Blepharitis · Meibomian Gland Dysfunction
Primary: Adverse Events — 1; 1; 2; 0 adverse events
Lower Eyelid Steatoblepharon (Excess Eyelid Fat)
Primary: Lower Eyelid Steatoblepharon Severity (LESS) Score--Clinician-Reported — 27; 6 participants — p=0.020
Blepharitis
Primary: Visual Analogue Scale (VAS - Ranges 0-100 mm) — 36.5; 28.5 units on a scale (from 0 to 100 mm) — p=0.072
Chlamydial Conjunctivitis
Primary: Total Number of Participants With Negative Chlamydia Direct Fluorescent Antibody (DFA) Test Results After Oral Azithromycin Treatments — 27 participants
Meibomian Gland Dysfunction
Primary: Percentage of Meibum Quality Responders in the Study Eye — 46.3; 33.9; 32.1; 42.9 Percentage of Patients
Acquired Blepharoptosis
Primary: Percentage of Subjects With Treatment-Emergent Adverse Events [Safety and Tolerability]) — 0; 0; 0 Participants
Eyelid Sebaceous Gland Carcinoma
Primary: Sentinel Lymph Node Positivity — 2 Participants
Meibomian Gland Dysfunction
Primary: Change From Baseline to Week 4 in Meibomian Gland Score (MGS) — 17.3; 18.0; 17.7; 18.1 score on a scale